Celldex Therapeutics CLDX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Celldex Therapeutics (CLDX) reported comprehensive income (loss), net of tax, attributable to parent of -$79.79M in Q1 2026.
- How has Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 49.0% year-over-year, from -$53.54M to -$79.79M.
- What is the long-term trend for Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Celldex Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 38.0% compound annual growth rate (CAGR), from -$71.21M to -$258.45M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, including net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a broader measure of financial performance than net income alone by accounting for all recognized revenues, expenses, gains, and losses. Investors use this to evaluate the overall change in the company's net worth during the reporting period.